"ELAV-Like Protein 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An RRM protein that binds to the 3'-UTR region of mRNAs and increases their stability. In EMBRYONIC STEM CELLS, it binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs and preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), to stabilize them and promote differentiation.
| Descriptor ID |
D000067780
|
| MeSH Number(s) |
D12.776.157.725.813.500.250 D12.776.664.962.813.500.250
|
| Concept/Terms |
ELAV-Like Protein 1- ELAV-Like Protein 1
- ELAV Like Protein 1
- HuR Paraneoplastic Encephalomyelitis Antigen
- HuR Protein
- Protein, HuR
- ELAVL1 protein
- protein, ELAVL1
- HuR Antigen
- Antigen, HuR
|
Below are MeSH descriptors whose meaning is more general than "ELAV-Like Protein 1".
Below are MeSH descriptors whose meaning is more specific than "ELAV-Like Protein 1".
This graph shows the total number of publications written about "ELAV-Like Protein 1" by people in this website by year, and whether "ELAV-Like Protein 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "ELAV-Like Protein 1" by people in Profiles.
-
Drug delivery approaches for HuR-targeted therapy for lung cancer. Adv Drug Deliv Rev. 2022 01; 180:114068.
-
The RNA-binding protein HuR is required for maintenance of the germinal centre response. Nat Commun. 2021 11 12; 12(1):6556.
-
Tumor-Targeted Dendrimer Nanoparticles for Combinatorial Delivery of siRNA and Chemotherapy for Cancer Treatment. Methods Mol Biol. 2020; 2059:167-189.
-
RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer. Mol Cancer Res. 2019 02; 17(2):508-520.
-
Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine. 2018 02; 14(2):373-384.
-
HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci Rep. 2017 08 30; 7(1):9694.
-
Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 08; 16(8):1470-1486.
-
HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 2016 10 04; 7(40):64820-64835.
-
Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology. 2016 Jun 21; 14(1):47.
-
HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015 Dec; 22(12):581-90.